Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Company profile

Ticker

ARWR

Exchange

NASDAQ

Website

arrowheadpharma.com

CEO

Christopher Anzalone

Incorporated

Delaware

Location

California

Fiscal year end

Sep 30

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...

Former names

ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC

SEC CIK

0000879407

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Arrowhead Madison Inc. • Arrowhead Australia Pty Ltd ...

IRS number

460408024

ARWR stock data

1M 1Y 5Y

News

From Benzinga Pro

Stocks That Hit 52-Week Lows On Tuesday

14 Jun 22

On Tuesday, 951 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

13 Jun 22

During Monday's trading, 1214 companies set new 52-week lows.

HC Wainwright & Co. Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $110

3 Jun 22

HC Wainwright & Co. analyst Patrick Trucchio maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and raises the price target from $100 to $110.

Where Arrowhead Pharmaceuticals Stands With Analysts

24 May 22

Goldman Sachs Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $66

24 May 22

Press releases

From Benzinga Pro

Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences

7 Jun 22

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Healthcare Conference – June 8-10, 2022 Type: Fireside chat

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics

26 May 22

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi)

Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results

10 May 22

- Conference Call and Webcast Today, May 10, 2022 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022. The company is

Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives

9 May 22

Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors

2 May 22

Analyst ratings and price targets

Last 3 months

Average target

$70.50

Low target

$35.00

High target

$110.00

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

10 May 22

26 Jun 22

30 Sep 22

Financial summary

Financial statements Chart ARWR financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Sep 21	Sep 20	Sep 19	Sep 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	86.41M	86.41M	86.41M	86.41M	86.41M	86.41M
Cash burn (monthly)	1.73M	23.83M	(no burn)	9.64M	(no burn)	4.36M
Cash used (since last report)	4.96M	68.42M	n/a	27.69M	n/a	12.52M
Cash remaining	81.45M	17.98M	n/a	58.72M	n/a	73.88M
Runway (months of cash)	47.2	0.8	n/a	6.1	n/a	16.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

ARWR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Feb 22	Anzalone Christopher Richard	Common Stock	Sell	Dispose S	No	Yes	50.51	1,900	95.97K	4,057,634
11 Feb 22	Anzalone Christopher Richard	Common Stock	Sell	Dispose S	No	Yes	50.9	61,482	3.13M	4,059,534
11 Feb 22	Anzalone Christopher Richard	Common Stock	Sell	Dispose S	No	Yes	52.28	42,153	2.2M	4,121,016
11 Feb 22	Anzalone Christopher Richard	Common Stock	Sell	Dispose S	No	Yes	53.11	40,853	2.17M	4,163,169
11 Feb 22	Anzalone Christopher Richard	Common Stock	Option exercise	Acquire M	No	Yes	5.19	146,388	759.75K	4,204,022
11 Feb 22	Anzalone Christopher Richard	Stock Option (right to buy Common Stock) Common Stock	Option exercise	Dispose M	No	No	5.19	146,388	759.75K	615,033
7 Jan 22	Backer Marianne De	Common Stock	Grant	Acquire A	No	No	0	6,400	0	23,400
7 Jan 22	Mauro Ferrari	Common Stock	Grant	Acquire A	No	No	0	6,400	0	42,971
7 Jan 22	Given Douglas B	Common Stock	Grant	Acquire A	No	No	0	6,400	0	116,268

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

ARWR institutional ownership history Ownership history

64.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	300	310	-3.2%
Opened positions	37	51	-27.5%
Closed positions	47	34	+38.2%
Increased positions	115	102	+12.7%
Reduced positions	100	110	-9.1%

13F shares	Current	Prev Q	Change
Total value	3.14B	4.52B	-30.6%
Total shares	68.17M	68.17M	+0.0%
Total puts	467.2K	481.71K	-3.0%
Total calls	392.6K	892.7K	-56.0%
Total put/call ratio	1.2	0.5	+120.5%

Largest owners	Shares	Value	Change
BLK Blackrock	12.16M	$559.01M	+1.2%
Vanguard	9.72M	$446.94M	+0.8%
STT State Street	4.68M	$215.32M	+19.9%
JPM JPMorgan Chase & Co.	2.92M	$134.33M	-2.0%
Alliancebernstein	2.76M	$126.76M	+11.8%
IVZ Invesco	2.33M	$107.35M	+1.2%
Geode Capital Management	1.85M	$85.31M	+2.1%
FMR	1.4M	$64.32M	+2.4%
NTRS Northern Trust	1.39M	$63.72M	-2.6%
CS Credit Suisse	1.28M	$58.66M	+1.0%

Largest transactions	Shares	Bought/sold	Change
JNJ Johnson & Johnson	1.26M	-2M	-61.3%
STT State Street	4.68M	+777.18K	+19.9%
Norges Bank	0	-690.82K	EXIT
Point72 Asset Management	561.1K	+516.81K	+1166.8%
Caas Capital Management	484.85K	+484.85K	NEW
Renaissance Technologies	380.3K	+380.3K	NEW
Aquilo Capital Management	1.05M	+347.01K	+49.5%
RTW Investments	0	-346.84K	EXIT
L1 Capital Pty	0	-292.74K	EXIT
Alliancebernstein	2.76M	+291.82K	+11.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Sarepta Therapeutics • Biocryst Pharmaceuticals • Alnylam Pharmaceuticals • Altimmune • Dicerna Pharmaceuticals • Silence Therapeutics • Arcturus Therapeutics • Viridian Therapeutics • Codiak Biosciences • Akcea Therapeutics

Risks

Our success depends on the attraction and retention of senior management and scientists with relevant expertise.
Geopolitical risks associated with the ongoing Russia-Ukraine conflict have impacted our clinical trial plans and could have an adverse impact on our business, financial condition and results of operations.
Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.

Management Discussion

The increase in revenue and operating income for the three and six months ended March 31, 2022 compared to the three and six months ended March 31, 2021 was driven by the revenue recognized from the GSK, Takeda and Horizon License Agreements.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abroad, adequately, advantage, afford, amplify, aspect, Asthma, attract, attraction, breadth, chain, concept, conflict, credit, culture, curtail, decided, decline, defending, derive, desirable, difficulty, diminished, distracting, duration, economy, employment, encounter, enforce, enforceable, EU, Europe, evolving, expertise, exposing, extent, feasible, footprint, forced, foreign, frustrate, GATEWAY, Geopolitical, hire, Hong, hypercholersterolemia, impair, impairment, imposed, industry, inflationary, infringe, innovative, invalidated, invention, ix, joint, Kong, landscape, Macau, macroeconomic, magnitude, mainland, maintain, maintenance, managerial, meaningful, parallel, pressure, proof, proprietary, prosecution, protect, protecting, prove, qualified, RCC, receipt, reduction, remote, repair, retaliatory, retention, Russia, shut, siRNA, sought, sponsored, stake, stemming, superior, Taiwan, technical, Ukraine, unable, uncertain, uncertainty, unenforceable, unexercised, unforeseen, venture, vii, viii, Visirna, Vivo, workplace, world, xi

Removed: begun, carcinoma, cell, disorder, obstructive, renal

From filing 10-Q 2022 Q2

Financial reports

View all